Singapore markets open in 47 minutes

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.2000-0.1900 (-7.95%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.3900
Bid1.5500 x 900
Ask2.6800 x 1000
Day's range2.1702 - 2.4154
52-week range1.3600 - 3.9900
Avg. volume10,596
Market cap10.683M
Beta (5Y monthly)2.08
PE ratio (TTM)N/A
EPS (TTM)-4.8100
Earnings date09 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.00
  • GlobeNewswire

    Aeterna Zentaris Reports Third Quarter 2023 Financial Results

    - Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmac

  • Zacks

    Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates

    Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug

    Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.